After-hours buzz: Synnex, Dyax, Novavax & more
Check out the companies making headlines after the bell Tuesday:
Synnex (NYSE: SNX) - Shares fell about 3 percent after the company missed analysts' expectations and issued weak second-quarter guidance. The IT service provider reported adjusted first quarter earnings of $1.46 a share, missing forecasts for $1.52 a share, on revenue of $3.20 billion, which was well below the $3.43 billion Wall Street had expected.
Novavax (NASDAQ: NVAX) - Shares of the clinical-stage vaccine company edged lower after it closed a public offering of 28 million shares of common stock, netting the company about $201 million in gross proceeds.
Dyax (NASDAQ: DYAX) - The biopharmaceuticals firm announced positive results from an early-stage trial of its hereditary angioedema treatment, DX-2930. The stock surged about 37 percent in after-hours trading.
Rubicon Project (NYSE: RUBI) - Shares rose about 1 percent after the big data computing provider reached an agreement to acquire Chango, a provider of marketing technology, in a deal valued at around $122 million. Shares rose about 1 percent after the announcement.
More From CNBC
